Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Caroline Reuter, MD, MSCI
Moderna, Inc.
Disclosure(s): Moderna, inc.: Employee, Stocks/Bonds (Public Company)
Poster(s):
(P-97) Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an Investigational Vaccine Against RSV, Given at 12 Months Following a Primary Dose in Adults Aged ≥ 50 Years
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
